AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
TT
20

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.
The drug, datopotamab deruxtecan, which AstraZeneca is jointly developing with Japan's Daiichi Sankyo, is being closely watched by analysts and investors in part due to the promise of the class of drugs to which it belongs, known as antibody drug conjugates (ADC).
ADCs consist of tumor-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
The trial data released on Friday showed the drug, abbreviated as Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in slowing the progression of a type of breast cancer in trial participants, compared to patients who received other treatments such as chemotherapy.
The trial focused on tumors that grow in response to the hormones estrogen or progesterone, which account for roughly two-thirds of breast cancer cases. The study participants' disease had spread to other parts of the body.
The British drugmaker also said that there was a "trend in improvement" in the other main goal of the study, "overall survival" of patients, but the data on that was not mature so the trial would continue as planned.
AstraZeneca shares rose 1.7% in early trading, to their highest level in more than five weeks.
AstraZeneca is simultaneously developing the drug for use in lung cancer, and while data from a separate late-stage trial released in July was positive, the market was concerned that the drug's benefits for use in lung cancer treatment might not as pronounced as hoped, leading shares to fall more than 6% on the day the data was released.
The company has not said when it will release detailed data from the lung cancer study.
Analysts see the positive results from the breast cancer trial as good for AstraZeneca, but the market is more focused on the results of a trial called MARIPOSA by Johnson & Johnson. It compares AstraZeneca’s blockbuster cancer drug Tagrisso alone with its own drug, Rybrevant, in combination with another medicine.
Those results are expected later this year.



Lion Attacks Woman in Australian Zoo, Severely Injuring her Arm

FILE PHOTO: A view of the city skyline of Brisbane, Australia, July 4, 2021. REUTERS/Jaimi Joy/File Photo
FILE PHOTO: A view of the city skyline of Brisbane, Australia, July 4, 2021. REUTERS/Jaimi Joy/File Photo
TT
20

Lion Attacks Woman in Australian Zoo, Severely Injuring her Arm

FILE PHOTO: A view of the city skyline of Brisbane, Australia, July 4, 2021. REUTERS/Jaimi Joy/File Photo
FILE PHOTO: A view of the city skyline of Brisbane, Australia, July 4, 2021. REUTERS/Jaimi Joy/File Photo

A woman has sustained severe injuries to an arm when she was attacked by a lion at an Australian zoo.

The Darling Downs Zoo in Queensland state said the 50-year-old woman was watching animal keepers working in the zoo’s carnivore precinct before opening hours Sunday morning when she was attacked.

She was flown by helicopter from the rural town of Pilton to the state capital Brisbane where she underwent surgery. Her condition was stable, the zoo said in a statement Sunday. Several news media reported the woman lost the injured arm.

The zoo said staff were working with government workplace safety investigators to determine how the incident happened. The state government confirmed an investigation was underway.

“Inexplicably, at this stage, one animal grabbed her by one arm and caused severe damage to it,” the zoo statement said.

“At no stage did this animal leave its enclosure and there was no risk at all to staff members or members of the public.”

The woman was not a staff member but a “much loved member” of the zoo’s “family,” the statement added, according to The Associated Press.

She had watched keepers at work many times over the past 20 years and was “well versed in safety protocols around potentially dangerous animals,” the zoo said.

Staff at the 48-hectare (119-acre) zoo declined media interviews on Monday.

The zoo planned to reopen Tuesday for the first time since the attack.

“The animal will definitely not be put down or punished in any way,” the statement said.

Five years ago, two lions mauled and critically injured a keeper inside their enclosure at the Shoalhaven Zoo in the state of New South Wales.